journal article·2023-05Open access

“Spongy skin” as a robust strategy to deliver 4-octyl itaconate for conducting dual-regulation against in-stent restenosis

Hong-Lin Qian, Sheng-Yu Chen, Fan Jia, Wei-Pin Huang, Jing Wang, Ke-Feng Ren, Guo-Sheng Fu, Jian Ji

Biomaterials· Volume 296

Abstract

The valid management of inflammation and precise inhibition of smooth muscle cells (SMCs) is regarded as a promising strategy for regulating vascular responses after stent implantation, yet posing huge challenges to current coating constructions. Herein, we proposed a spongy cardiovascular stent for the protective delivery of 4-octyl itaconate (OI) based on a “spongy skin” approach, and revealed the dual-regulation effects of OI for improving vascular remolding. We first constructed a “spongy skin” onto poly-l-lactic acid (PLLA) substrates, and realized the protective loading of OI with the highest dosage of 47.9 μg/cm 2 . Then, we verified the remarkable inflammation mediation of OI, and surprisingly revealed that the OI incorporation specifically inhibited SMC proliferation and phenotype switching, which contributed to the competitive growth of endothelial cells (EC/SMC ratio ∼ 5.1). We further demonstrated that OI at a concentration of 25 μg/mL showed significant suppression of the TGF-β/Smad pathway of SMCs, leading to the promotion of contractile phenotype and reduction of extracellular matrix. In vivo evaluation indicated that the successful delivery of OI fulfilled the inflammation regulation and SMCs inhibition, therefore suppressing the in-stent restenosis. This “spongy skin” based OI eluting system may serve as a new strategy for improving vascular remolding, and provides a potential concept for the treatment of cardiovascular diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Angiogenesis and VEGF in Cancer · Coronary Interventions and Diagnostics · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (65)

Show source-provided references
1. Heart disease and stroke statistics-2022 update: a report from the American Heart Association10.1161/CIR.0000000000001052 ↗
2. Drug-eluting coronary-artery stents10.1056/NEJMra1210816 ↗
3. Intravascular stents to prevent occlusion and re-stenosis after transluminal angioplasty10.1056/NEJM198703193161201 ↗
4. Designing better cardiovascular stent materials - a learning curve10.1002/adfm.202005361 ↗
5. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis, JACC Cardiovasc
6. Restenosis of drug-eluting stents10.1161/CIRCINTERVENTIONS.118.007023 ↗
7. Yang · 2020
8. Phenolic-amine chemistry mediated synergistic modification with polyphenols and thrombin inhibitor for combating the thrombosis and inflammation of cardiovascular stents10.1016/j.biomaterials.2020.120626 ↗
9. Nitric oxide release: part II. Therapeutic applications10.1039/c2cs15273h ↗
10. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis10.1161/01.CIR.0000060487.15126.56 ↗
11. Inflammation and restenosis in the stent era10.1161/01.ATV.0000037100.44766.5B ↗
12. Biological responses in stented arteries10.1093/cvr/cvt115 ↗
13. In-stent restenosis in the drug-eluting stent era10.1016/j.jacc.2010.07.028 ↗
14. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization10.1056/NEJMoa012843 ↗
15. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease10.1056/NEJMoa032441 ↗
16. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study10.1016/S0140-6736(07)60314-6 ↗
17. Stent thrombosis in randomized clinical trials of drug-eluting stents10.1056/NEJMoa067731 ↗
18. Advances in stent drug delivery: the future is in bioabsorbable stents10.1517/17425240802668495 ↗
19. Biochemistry of proinflammatory macrophage activation10.1007/s00018-018-2784-1 ↗
20. Exploring the full spectrum of macrophage activation10.1038/nri2448 ↗
21. Two-stage metabolic remodelling in macrophages in response to lipopolysaccharide and interferon-gamma stimulation10.1038/s42255-019-0083-2 ↗
22. Macrophage plasticity and polarization in tissue repair and remodelling10.1002/path.4133 ↗
23. Macrophages in tissue repair, regeneration, and fibrosis10.1016/j.immuni.2016.02.015 ↗
24. Itaconic acid is a mammalian metabolite induced during macrophage activation10.1021/ja2070889 ↗
25. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation10.1016/j.cmet.2016.06.004 ↗
26. Therapeutic potential of tricarboxylic acid cycle metabolite itaconate in cardiovascular diseases10.1016/j.ebiom.2020.102938 ↗
27. Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis10.1038/s41586-018-0052-z ↗
28. Itaconate charges down inflammation10.1038/s41577-018-0016-4 ↗
29. Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury10.1016/j.molmet.2019.11.019 ↗
30. Itaconate: the poster child of metabolic reprogramming in macrophage function10.1038/s41577-019-0128-5 ↗
31. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP110.1038/nature25986 ↗
32. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism10.1016/j.tibs.2014.02.002 ↗
33. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription10.1038/ncomms11624 ↗
34. Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression10.1074/jbc.M110.207738 ↗
35. The “Prochaska” microtiter plate bioassay for inducers of NQO110.1016/S0076-6879(04)82014-7 ↗
36. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers10.1016/0003-2697(88)90292-8 ↗
37. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis, JACC Cardiovasc
38. Restenosis, stent thrombosis, and bleeding complications navigating between Scylla and Charybdis10.1016/j.jacc.2018.02.023 ↗
39. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
40. Drug-eluting coronary stents: insights from preclinical and pathology studies10.1038/s41569-019-0234-x ↗
41. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants10.1073/pnas.172398899 ↗
42. Thermo-triggered ultrafast self-healing of microporous coating for on-demand encapsulation of biomacromolecules10.1016/j.biomaterials.2018.10.038 ↗
43. Humidity-triggered self-healing of microporous polyelectrolyte multilayer coatings for hydrophobic drug delivery10.1002/adfm.201503258 ↗
44. Self-healing spongy coating for drug "cocktail" delivery10.1021/acsami.5b11602 ↗
45. Kinetics of penetration into uniform porous media: testing the equivalent-capillary concept10.1021/la034490v ↗
46. Generalized modeling of spontaneous imbibition based on Hagen−Poiseuille flow in tortuous capillaries with variably shaped apertures10.1021/la5007204 ↗
47. miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis
48. Wang · 2020
49. BMP-2-immobilized porous matrix with leaf-stacked structure as a bioactive GBR membrane10.1021/acsami.8b09558 ↗
50. Fabrication of “spongy skin” on diversified materials based on surface swelling non-solvent-induced phase separation10.1021/acsami.1c18333 ↗
51. Precision medicine - personalized, problematic, and promising10.1056/NEJMsb1503104 ↗
52. M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis10.1136/annrheumdis-2018-214333 ↗
53. Macrophage polarization in response to ECM coated polypropylene mesh10.1016/j.biomaterials.2014.04.115 ↗
54. Inflammation in atherosclerosis10.1038/nature01323 ↗
55. Transcriptional and epigenetic regulation of macrophages in atherosclerosis10.1038/s41569-019-0265-3 ↗
56. Surface-mediated transfection of a pDNA vector encoding short hairpin RNA to downregulate TGF-β1 expression for the prevention of in-stent restenosis10.1016/j.biomaterials.2016.11.042 ↗
57. Photothermal spongy film for enhanced surface-mediated transfection to primary cells10.1021/acsabm.9b00358 ↗
58. Smooth muscle differentiation control comes full circle10.1161/CIRCRESAHA.117.311722 ↗
59. 4-Octyl itaconate protects against renal fibrosis via inhibiting TGF-beta/Smad pathway, autophagy and reducing generation of reactive oxygen species10.1016/j.ejphar.2020.172989 ↗
60. Chemoproteomic profiling of itaconation by bioorthogonal probes in inflammatory macrophages10.1021/jacs.9b11962 ↗
61. Matrix stiffness regulates SMC functions via TGF-beta signaling pathway10.1016/j.biomaterials.2019.119407 ↗
62. In-stent atherosclerosis at a crossroads10.1161/CIRCULATIONAHA.116.025129 ↗
63. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation10.1161/01.RES.0000119170.70818.4F ↗
64. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
65. The role of infiltrating immune cells in dysfunctional adipose tissue10.1093/cvr/cvx108 ↗